Sign In
Buy QDEL
$13.60
+0.310 (+2.33%)
At Close: Jun 03, 2026
QuidelOrtho to Present at the 47th Annual Raymond James Institutional Investor Conference
04:05pm, Wednesday, 18'th Feb 2026
SAN DIEGO, Feb. 18, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, today announced that members of it
Public Sector Pension Investment Board Increases Stake in QuidelOrtho Corporation $QDEL
04:04am, Wednesday, 18'th Feb 2026
Public Sector Pension Investment Board lifted its stake in shares of QuidelOrtho Corporation (NASDAQ: QDEL) by 17.2% in the third quarter, according to the company in its most recent disclosure with t
QDEL Expands Immunoassay Portfolio Via Lifotronic Supply Agreement
12:15pm, Tuesday, 17'th Feb 2026
QuidelOrtho inks Lifotronic supply deal, adding 70+ assays and new analyzer platforms to boost global immunoassay reach and recurring revenue potential.
QuidelOrtho firma un acuerdo de suministro estratégico para ampliar su cartera global de inmunoensayos
03:42am, Monday, 16'th Feb 2026
/PRNewswire/ -- QuidelOrtho ha firmado un acuerdo de suministro estratégico a largo plazo con Lifotronic Technology Co., Ltd. (Lifotronic Technology Co., Ltd.,
QuidelOrtho geht strategische Liefervereinbarung zur Erweiterung des globalen Immunoassay-Portfolios ein
01:00am, Monday, 16'th Feb 2026
/PRNewswire/ -- QuidelOrtho ist mit Lifotronic Technology Co., Ltd. eine langfristige strategische Liefervereinbarung eingegangen (Lifotronic Technology Co.,
Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP)
02:08am, Friday, 13'th Feb 2026
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two
QuidelOrtho Q4 Earnings and Revenues Beat Estimates, Margins Down
10:26am, Thursday, 12'th Feb 2026
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
10:04pm, Wednesday, 11'th Feb 2026
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
QuidelOrtho (QDEL) Q4 Earnings and Revenues Top Estimates
06:26pm, Wednesday, 11'th Feb 2026
QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
QuidelOrtho Reports Fourth Quarter and Full-Year 2025 Financial Results
04:05pm, Wednesday, 11'th Feb 2026
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expe
Earnings Preview: QuidelOrtho (QDEL) Q4 Earnings Expected to Decline
11:01am, Wednesday, 04'th Feb 2026
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QuidelOrtho Receives Excellence Services Label in EMEA and Two Stevie® Awards
07:12am, Tuesday, 03'rd Feb 2026
– First medical device company to receive excellence recognition in accordance with ISO 23592 – Gold Stevie® Award for Customer Service Success – Bronze Stevie® Award for AI & Tech Focused Dig
Strengthening the blood supply: Awareness, challenges and donor impact
07:12am, Thursday, 22'nd Jan 2026
SAN DIEGO, Jan. 22, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, has released episode 55 of its Science Bytes podcast, featuring Michelle Mulle
QuidelOrtho to Report Fourth Quarter and Full-Year 2025 Financial Results
07:00am, Wednesday, 21'st Jan 2026
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, announced today that it will report its fin
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
11:40am, Thursday, 15'th Jan 2026
QDEL's decent Q3 2025 results and expanding diagnostics portfolio support near-term growth despite respiratory reliance and payer risks.
